Zurnai Injection, Solution
Product Images NDC 59011-962

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Zurnai (NDC 59011-962). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Knoa Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Nalmefene 01)

Chemical structure of Nalmefene Hydrochloride, the active ingredient in Zurnai injection solution. The diagram depicts the molecular arrangement, including rings, hydroxyl groups, and a hydrochloride component.*

FDA Label Image

Figure 1 (Nalmefene 02)

A line graph depicting minute ventilation (L/min) over time relative to Zurnai 1.5 mg intramuscular administration (time 0). The graph shows ventilation increasing significantly after dosing, peaking around 6-10 minutes, and stabilizing above the pre-fentanyl baseline level for the remainder of the 30-minute period. Key annotations include 'Nadir' before administration, 'Zurnai 1.5 mg Administered' at time zero, and the 'Mean Pre-Fentanyl Baseline Minute Ventilation' as a dashed horizontal line.*

FDA Label Image

Figure 2 (Nalmefene 03)

A line graph depicting the mean (SD) percent of baseline minute ventilation over time (minutes) after administration of Zurnai 1.5 mg injection. The graph shows ventilation rates starting at baseline, decreasing sharply at zero minutes, then progressively increasing to above baseline levels at 5 minutes and maintaining near or above baseline through 30 minutes, with error bars indicating variability.*

FDA Label Image

Figure 3 (Nalmefene 04)

A line graph comparing mean (SD) nalmefene plasma concentrations (ng/mL) over 12 hours for three dosing conditions: ZURNAI 1.5 mg intramuscular (IM), Nalmefene 1.0 mg intramuscular (IM), and Nalmefene 1.0 mg intravenous (IV). The x-axis shows time in hours, and the y-axis shows concentration in ng/mL, depicting the pharmacokinetic profiles with error bars.*

FDA Label Image

Figure 4 (Nalmefene 05)

This line graph compares mean nalmefene plasma concentration (ng/mL) over time (minutes) for three dosing regimens: Zurnai 1.5 mg intramuscular injection, nalmefene 1.0 mg intramuscular injection, and nalmefene 1.0 mg intravenous injection. The graph includes error bars showing standard deviation for each time point up to 60 minutes.*

FDA Label Image

Image (Nalmefene 06)

Packaging label for Zurnai 1.5 mg/0.5 mL injection solution by Knoa Pharma LLC. The label includes product name, generic name Nalmefene Hydrochloride, NDC 59011-962-01, and specifies single-dose auto-injector for intramuscular or subcutaneous use. The label highlights dosage strength, viewing window, needle guard, safety seal, blue cap, lot number, and expiration date areas.*

FDA Label Image

Image (Nalmefene 07)

Instructional illustration showing two steps for opening a container: first twist the cap, then pull to remove it. The illustration depicts hands performing these actions with directional arrows indicating the motion.*

FDA Label Image

Image (Nalmefene 08)

An instructional diagram showing injection preparation for Zurnai (Nalmefene Hydrochloride) solution. It depicts a before injection view through a viewing window of the vial, pressing down the injection device with a 'click' sound, and holding the injection area for 3 seconds after administration. The illustration indicates intramuscular or subcutaneous injection technique.*

FDA Label Image

Image (Nalmefene 09)

Illustration showing a syringe viewed through a viewing window after an injection, highlighting the positioning of the plunger within the barrel. The diagram emphasizes proper post-injection positioning for the Zurnai injection solution device.*

FDA Label Image

Image (Nalmefene 10)

FDA Label Image

Image (Nalmefene 11)

An instructional illustration showing a person lying on their side with one leg bent at the knee and the other extended, supporting their head with both hands. This position is commonly used for recovery or to maintain an open airway.*

FDA Label Image

Image (Nalmefene 12)

An instructional illustration showing a clock face with the minute hand pointing to 12 and a shaded green segment representing a waiting time of 2 to 5 minutes. This image likely indicates a recommended waiting period after dosing or administration related to the product.*

FDA Label Image

Image (Nalmefene 13)

An instructional illustration showing a used injection pen with its needle cap removed, positioned above a sharps disposal container labeled "SHARPS," indicating proper disposal of the injection device after use.*

FDA Label Image

Principal Display Panel (1.5 mg/0.5 mL Auto-Injector Label)

Zurnai (nalmefene injection) 1.5 mg/0.5 mL solution in a single-dose auto-injector for intramuscular or subcutaneous use. The label includes usage instructions with step-by-step illustrations, warnings, storage conditions, and a lot number and expiration date area. The labeler is Knoa Pharma LLC.*

FDA Label Image

Principal Display Panel (1.5 mg/0.5 mL Auto-Injector Carton)

Zurnai 1.5 mg/0.5 mL Auto-Injector is a nalmefene hydrochloride injection for intramuscular or subcutaneous use. The carton includes use instructions with illustrations for the auto-injector and notes the product is a single-dose device. Manufactured for Knoa Pharma LLC, it is labeled Rx only with detailed patient and dosing information visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.